Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients

Journal of Clinical Psychopharmacology

Volumn 25, Issue 6, 2005, Pages 527-532

  Saito, Manabu ^a   Yasui Furukori, Norio ^a   Nakagami, Taku ^a   Furukori, Hanako ^a   Kaneko, Sunao ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PALIPERIDONE; PAROXETINE; RISPERIDONE;

ACCOMMODATION; ADULT; AGED; AKATHISIA; ARTICLE; ASTHENIA; AUTONOMIC DYSFUNCTION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEART PALPITATION; HOSPITAL PATIENT; HUMAN; HYPERKINESIA; HYPOKINESIA; LIQUID CHROMATOGRAPHY; MALE; MEMORY DISORDER; MENTAL CONCENTRATION; MICTURITION DISORDER; MUSCLE RIGIDITY; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; TANDEM MASS SPECTROMETRY; TENSION; TREMOR;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PAROXETINE; PYRIMIDINES; RISPERIDONE; SCHIZOPHRENIA;

EID: 27944435343     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000185428.02430.c7     Document Type: Article

References (41)

1. Moller HJ. Non-neuroleptic approaches to treating negative symptoms in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2004;254:108-116.
2. Silver H. Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug Rev. 2001;7:283-304.
3. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Drug interactions with newer antidepressants: role of human cytochromes P450. J Clin Psychiatry. 1998;59(suppl 15):19-27.
4. Leysen JE, Gommeren W, Eens A, et al. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther. 1988;247:661-670.
5. Chouinard G, Arnott W. Clinical review of risperidone. Can J Psychiatry. 1993;38(suppl 3):S89-95.
6. Mannens G, Huang ML, Meuldermans W, et al. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos. 1993;21:1134-1141.
7. Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol. 1999;359:147-151.
8. Yasui-Furukori N, Hidestrand M, Spina E, et al. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos. 2001;29:1263-1368.
9. Scordo MG, Spina E, Facciola G, et al. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl). 1999;147:300-305.
10. Roh HK, Kim CE, Chung WG, et al. Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. Eur J Clin Pharmacol. 2001;57:671-675.
11. Yasui-Furukori N, Mihara K, Kondo T, et al. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia. J Clin Pharmacol. 2003;43:122-127.
12. Mihara K, Kondo T, Yasui-Furukori N, et al. Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia. Ther Drug Monit. 2003;25:287-293.
13. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry. 1999;60:256-259.
14. McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000;57:794-801.
15. Spina E, Avenoso A, Facciola G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther Drug Monit. 2001;23:223-227.
16. Bork JA, Rogers T, Wedlund PJ, et al. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry. 1999;60:469-476.
17. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
18. Addington D, Addington J, Atkinson M. A psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale. Schizophr Res. 1996;19:205-212.
19. Lingjærde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100.
20. Lindenmayer JP, Bernstein-Hyman R, Grochowski S, et al. Psychopathology of schizophrenia: initial validation of a 5-factor model. Psychopathology. 1995;28:22-31.
21. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet. 1990;336:529-532.
22. Steen VM, Andreassen OA, Daly AK, et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics. 1995;5:215-223.
23. Johansson I, Oscarson M, Yue QY, et al. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol. 1994;46:452-459.
24. Kubota T, Yamaura Y, Ohkawa N, et al. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol. 2000;50:31-34.
25. Spina E, Avenoso A, Scordo MG, et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol. 2002;22:419-423.
26. Nakagami T, Yasui-Furukori N, Saito M, et al. Thioridazine inhibits risperidone metabolism: a clinically relevant drug interaction. J Clin Psychopharmacol. 2005;25:89-91.
27. Bloomer JC, Woods FR, Haddock RE, et al. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol. 1992;33:521-523.
28. Skjelbo E, Brosen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol. 1992;34:256-261.
29. Nielsen KK, Flinois JP, Beaune P, et al. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. Pharmacol Exp Ther. 1996;277:1659-1664.
30. Ball SE, Ahern D, Scatina J, et al. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br J Clin Pharmacol. 1997;43:619-626.
31. Alfaro CL, Lam YW, Simpson J, et al. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol. 2000;40:58-66.
32. Jeppesen U, Gram LF, Vistisen K, et al. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol. 1996;51:73-78.
33. Laine K, Tybring G, Hartter S, et al. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetic s and the debrisoquine test. Clin Pharmacol Ther. 2001;70:327-335.
34. Bertelsen KM, Venkatakrishnan K, Von Moltke LL, et al. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos. 2003;31:289-293.
35. Boulton DW, DeVane CL, Liston HL, et al. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002;71:163-169.
36. Weiss J, Kerpen CJ, Lindenmaier H, et al. Interaction of antiepileptic drugs with human P-glycoprotein in vitro. J Pharmacol Exp Ther. 2003;307:262-267.
37. Tanigawara Y, Okamura N, Hirai M, et al. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther. November 1992;263(2):840-845.
38. Juurlink DN, Mamdani MM, Kopp A, et al. A population-based assessment of the potential interaction between serotonin specific reuptake inhibitors and digoxin. Br J Clin Pharmacol. 2005;59:102-107.
39. Prusoff BA, Williams DH, Weissman MM, et al. Treatment of secondary depression in schizophrenia. A double blind, placebo controlled trial of amitriptyline added to perphenazine. Arch Gen Psychiatry. 1979;36:569-575.
40. Kramer MS, Vogel WH, DiJohnson C, et al. Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial. Arch Gen Psychiatry. 1989;46:922-928.
41. Yasui-Furukori N, Kondo T, Mihara K, et al. Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia. Psychopharmacology. 2004;171:223-227.